Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer

Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer

The immune checkpoint inhibitor atezolizumab is approved for PD-L1-positive triple-negative breast cancer (TNBC). However, no activity of atezolizumab in PD-L1-negative TNBC has been reported to date. Here, we present the case study of a woman with TNBC with low tumor infiltrating lymphocytes and PD...

Full description

Bibliographic Details
Main Authors: Fara Brasó-Maristany, Miriam Sansó, Nuria Chic, Débora Martínez, Blanca González-Farré, Esther Sanfeliu, Lucio Ghiglione, Esther Carcelero, Javier Garcia-Corbacho, Marcelo Sánchez, Dolors Soy, Pedro Jares, Vicente Peg, Cristina Saura, Montserrat Muñoz, Aleix Prat, Ana Vivancos
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
immunotherapy
breast cancer
biomarkers
ctDNA
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.710596/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.710596/full

Similar Items